| Prev Close | 0.00 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 0.00 / 0.00 |
| Exchange | NASDAQ |
| Div & Yield | N.A. (N.A) |
Celsus Therapeutics (CLTX) Stock Hits One-Year Low Following Disappointing Trial Results
Shares of Celsus Therapeutics (CLTX) plunged more to a 52-week low in morning trading Tuesday after the biotech company announced the results of its dermatitis treatment in a mid-stage trial.
Celsus Therapeutics Announces That The Phase II Trial Of MRX-6 Cream 2% In Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint
MRX-6 Cream Did Not Demonstrate Separation From Vehicle in Primary Endpoint of Percent Improvement in the Investigator's Global Assessment
Celsus Therapeutics Completes Enrollment Of Phase II Trial Of MRX-6 Cream 2% In Pediatric Atopic Dermatitis
Topline Data From Double-Blind Portion of Trial Expected by End of February, 2015
Celsus Therapeutics Announces FDA Allowance Of IND For Clinical Development Of MRX-6 Cream In Atopic Dermatitis
Phase II Dose Ranging Clinical Trial in Atopic Dermatitis Expected to Begin in First Quarter of 2015
Celsus Therapeutics Plc Announces First Patient Enrolled In Phase II Trial Of MRX-6 In Pediatric Atopic Dermatitis
Results Expected in Fourth Quarter of 2014
